GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage: DNA Damage-Induced Apoptosis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008630 describes the intracellular signaling cascade that detects DNA damage and triggers intrinsic (mitochondrial) apoptosis, ending when the execution phase of cell death begins.
• The pathway is a core tumor-suppressor mechanism: p53 activation, BAX/BAK pore formation, cytochrome c release, APAF1 apoptosome assembly and caspase-9 activation are central steps.
• Defects in this pathway cause chemoresistance and therapy failure in cancers such as chronic myeloid leukemia and cisplatin-resistant solid tumors.
• Key regulators include TP53, the BCL2 family (BAX, BAK, BID, PUMA, NOXA), APAF1, CASP9, CASP3 and DFFB, whose loss suppresses interferon signaling and enables persister cell regrowth.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the standard tools for dissecting causal gene contributions to this pathway.
• The pathway is studied with apoptosis assays, DNA damage markers (gamma-H2AX), cytochrome c release imaging, caspase activity assays and multi-omics profiling.
Description
GO:0008630, intrinsic apoptotic signaling pathway in response to DNA damage, is a biological process in which an intracellular signal triggered by the detection of DNA damage is conveyed to activate the apoptotic death of the cell. The pathway begins with DNA damage sensing and ends when the execution phase of apoptosis is triggered, making it a central node linking genome integrity surveillance to cell fate decisions. Because it determines whether a damaged cell dies or survives, this process is a major determinant of tumor suppression, chemotherapy response and tissue homeostasis. Cancer cells frequently disable this pathway to survive genotoxic stress, and restoring its activity is a long-standing therapeutic goal in oncology. In parallel, the same machinery influences non-cancer biology, including embryonic stem cell behavior and immune signaling in persister cells. Understanding the molecular steps, key genes and regulatory inputs of GO:0008630 is therefore essential for researchers in cancer biology, DNA repair and drug discovery.
intrinsic apoptotic signaling pathway in response to DNA damage At A Glance
| GO ID | GO:0008630 |
|---|---|
| GO term | intrinsic apoptotic signaling pathway in response to DNA damage |
| Ontology | biological_process |
| Synonym | DNA damage response, signal transduction resulting in induction of apoptosis |
| Major function | Conveys a DNA-damage-induced intracellular signal to trigger intrinsic apoptotic cell death |
| Pathway start | Detection of DNA damage |
| Pathway end | Execution phase of apoptosis is triggered |
| Core organelles | Nucleus and mitochondria |
| Key effectors | TP53, BAX, BAK, APAF1, CASP9, CASP3 |
What Is GO:0008630?
In our own words, GO:0008630 is the series of molecular signals in which an intracellular signal is conveyed to trigger apoptotic death of a cell. The pathway is induced by the detection of DNA damage and ends when the execution phase of apoptosis is triggered. It is the DNA damage response branch that commits a damaged cell to intrinsic, mitochondrial apoptosis rather than repair or survival.
Why Is intrinsic apoptotic signaling pathway in response to DNA damage Important in Cell Biology?
GO:0008630 is important because it is the principal mechanism by which cells with damaged DNA are eliminated, and its failure is a hallmark of cancer, chemoresistance and therapy relapse. Many anticancer drugs, including cisplatin and tyrosine kinase inhibitors, depend on an intact DNA-damage-induced intrinsic apoptotic pathway to kill tumor cells. At the same time, this pathway shapes normal development and stem cell biology, as shown by DNA damage response activation and anastasis in embryonic stem cells. Consequently, genes in GO:0008630 are both biomarkers of treatment response and targets for CRISPR-based functional studies.
• Acts as a tumor-suppressor barrier by eliminating cells with irreparable DNA damage.
• Determines sensitivity to DNA-damaging chemotherapy such as cisplatin.
• Mediates TKI-induced cell death in chronic myeloid leukemia, and its loss causes resistance.
• Controls whether cancer persister cells regrow after therapy, partly through DFFB and interferon signaling.
• Regulates embryonic stem cell survival and anastasis after DNA damage.
• Provides mechanistic biomarkers such as gamma-H2AX, cytochrome c release and caspase activation.
• Is a major focus of apoptosis-targeted cancer therapy development.
• Offers causal gene targets for CRISPR knockout, point-mutation and knock-in modeling.
What Happens During intrinsic apoptotic signaling pathway in response to DNA damage?
DNA damage detection and p53 activation
In simple terms: The cell first notices that its DNA is broken and switches on a stress response.
The pathway begins when DNA lesions are detected and an intracellular signal is generated. A central transducer is TP53, which is stabilized and activated after DNA damage and transcriptionally induces pro-apoptotic targets such as Caliban and other BCL2-family regulators. This damage-sensing step commits the cell toward the apoptotic branch of the DNA damage response rather than repair or survival.
Mitochondrial outer membrane permeabilization
In simple terms: The mitochondria are punctured, releasing death-promoting factors.
Activated p53 and its targets shift the balance of the BCL2 family toward effectors such as BAX and BAK, which form pores in the mitochondrial outer membrane. This mitochondrial outer membrane permeabilization is the point of no return for intrinsic apoptosis and releases cytochrome c and other intermembrane proteins into the cytosol. The intrinsic apoptotic signaling pathway in cancer cells can be activated by natural compounds through this mitochondrial step.
Apoptosome assembly and caspase-9 activation
In simple terms: Released factors build a death platform that switches on executioner enzymes.
Cytosolic cytochrome c binds APAF1 to assemble the apoptosome, which recruits and activates the initiator caspase CASP9. Active caspase-9 then cleaves downstream executioner caspases such as CASP3 and CASP7, amplifying the death signal. This step converts the DNA damage signal into a proteolytic cascade.
Execution phase and DNA fragmentation
In simple terms: The cell dismantles itself, including its DNA.
Executioner caspases cleave structural and regulatory substrates, and the pathway ends when the execution phase of apoptosis is triggered. DNA fragmentation factor subunit B (DFFB) participates in this terminal phase, and its activity has been linked to suppression of interferon signaling that enables cancer persister cell regrowth. This terminal step is what distinguishes completed apoptosis from reversible damage responses such as anastasis.
Key Genes Involved in GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
The following genes and proteins are experimentally established components or regulators of GO:0008630 and are commonly manipulated in CRISPR studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | DNA damage sensor and transcriptional activator of pro-apoptotic genes | Most frequently mutated tumor suppressor; central to pathway activation |
| BAX | BCL2-family effector that permeabilizes mitochondria | Knockout models test dependence on mitochondrial apoptosis |
| BAK | BCL2-family effector cooperating with BAX | Double BAX/BAK knockout blocks intrinsic apoptosis |
| BID | BH3-only protein linking death receptor and mitochondrial pathways | Used to study crosstalk between extrinsic and intrinsic apoptosis |
| BBC3 (PUMA) | p53-induced BH3-only sensitizer | Marker of p53-dependent apoptotic commitment |
| PMAIP1 (NOXA) | BH3-only protein promoting mitochondrial permeabilization | Studied in chemosensitivity models |
| APAF1 | Apoptosome scaffold that activates caspase-9 | Loss blocks cytochrome c-dependent caspase activation |
| CASP9 | Initiator caspase of the intrinsic pathway | Key readout of apoptosome function |
| CASP3 | Executioner caspase | Activity assays are standard apoptosis readouts |
| CASP7 | Executioner caspase cooperating with CASP3 | Used to assess execution-phase completion |
| DFFB | DNA fragmentation factor subunit B in terminal apoptosis | Links apoptosis to interferon suppression and persister regrowth |
| BCL2 | Anti-apoptotic guardian of mitochondrial integrity | Overexpression models test apoptosis resistance |
| BCL2L1 (BCL-XL) | Anti-apoptotic BCL2-family member | Target of BH3 mimetics in cancer therapy |
| MCL1 | Anti-apoptotic BCL2-family member | Frequent resistance factor in solid and hematologic tumors |
| STAT5A | Signaling factor whose loss restores TKI sensitivity | CRISPR knockout sensitizes resistant CML cells |
| INTS7 | Integrator subunit linked to DNA damage response in stem cells | Deficiency activates DNA damage response and anastasis |
| Caliban | p53 transcriptional target after DNA damage | Newly described p53-dependent apoptosis regulator |
How Is intrinsic apoptotic signaling pathway in response to DNA damage Regulated?
GO:0008630 is regulated at multiple levels. Transcriptional regulation by TP53 controls the expression of pro-apoptotic BH3-only proteins and other effectors after DNA damage. Post-translational regulation by BCL2-family interactions sets the threshold for mitochondrial outer membrane permeabilization, with anti-apoptotic proteins such as BCL2, BCL-XL and MCL1 opposing BAX and BAK. Signaling pathways such as STAT5A can modulate sensitivity to therapy-induced apoptosis, and CRISPR knockout of STAT5A restores TKI sensitivity in resistant chronic myeloid leukemia cells. In stem cells, deficiency of INTS7 activates the DNA damage response and permits anastasis, showing that the pathway can be reversed or restrained. Finally, terminal apoptotic effectors such as DFFB influence interferon signaling and persister cell regrowth, adding a non-cell-autonomous layer of regulation.
intrinsic apoptotic signaling pathway in response to DNA damage and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Tumor suppression and chemosensitivity | TP53 knockout and point-mutation knock-in cancer cell lines |
| STAT5A | TKI-resistant chronic myeloid leukemia | CRISPR/Cas9 knockout in resistant CML cells |
| DFFB | Cancer persister cell regrowth and interferon signaling | DFFB knockout and overexpression persister cell models |
| INTS7 | Embryonic stem cell DNA damage response and anastasis | INTS7 knockout embryonic stem cell models |
| BCL2 / MCL1 | Apoptosis resistance and therapy failure | Overexpression and BH3-mimetic sensitivity models |
Cancer and chemoresistance
Evasion of intrinsic apoptosis is a hallmark of cancer, and tumors frequently lose GO:0008630 function through TP53 mutation, BCL2-family imbalance or caspase inactivation. Cisplatin resistance in solid tumors involves multi-omics changes that blunt DNA-damage-induced apoptosis. In chronic myeloid leukemia, resistance to tyrosine kinase inhibitors can be reversed by CRISPR/Cas9 targeting of STAT5A, restoring sensitivity to therapy. These findings make the pathway a central target for apoptosis-directed cancer therapy.
Therapy relapse and persister cells
Cancer persister cells can survive genotoxic therapy and later regrow. DFFB, a terminal component of the apoptotic DNA fragmentation machinery, suppresses interferon signaling to enable persister cell regrowth, linking GO:0008630 effectors to relapse biology. This suggests that residual apoptotic signaling capacity influences whether surviving cells re-expand after treatment.
Stem cell survival and anastasis
DNA damage does not always end in apoptosis. INTS7 deficiency activates the DNA damage response and elicits resurgence of endogenous retrovirus MERVL together with anastasis of embryonic stem cells, showing that cells can recover from pro-apoptotic damage signals. This has implications for development, regeneration and the interpretation of DNA damage response experiments.
From intrinsic apoptotic signaling pathway in response to DNA damage-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for DNA-damage-induced apoptosis? | CRISPR knockout cell line plus DNA-damaging drug treatment |
| Does a specific mutation alter apoptotic commitment? | Point-mutation knock-in at the endogenous locus |
| Does a tag or reporter track pathway activation? | Tagged knock-in of pathway genes such as CASP3 or APAF1 |
| Does overexpression of an anti-apoptotic gene block the pathway? | Overexpression of BCL2 or MCL1 followed by apoptosis assays |
| Which genes modify chemosensitivity? | CRISPR library screening under cisplatin or TKI treatment |
| Can apoptosis be reversed or delayed? | Anastasis models in embryonic stem cells |
How to Study the intrinsic apoptotic signaling pathway in response to DNA damage Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Annexin V flow cytometry | Phosphatidylserine exposure during apoptosis | Quantifying cell death after DNA damage |
| Caspase-3/7 activity assay | Executioner caspase activity | Confirming pathway completion |
| Cytochrome c release imaging | Mitochondrial outer membrane permeabilization | Locating the point of no return |
| gamma-H2AX immunofluorescence | DNA double-strand breaks | Confirming upstream damage signal |
| Multi-omics profiling | Transcript and protein changes in resistance | Identifying pathway modifiers in cisplatin resistance |
| CRISPR knockout screening | Gene requirement for apoptosis | Discovering sensitizing targets |
| Reporter knock-in imaging | Real-time pathway activation | Tracking apoptosis dynamics in live cells |
| BH3 profiling | Mitochondrial priming state | Predicting response to apoptosis-inducing therapy |
Apoptosis and caspase activity assays
Flow cytometry with Annexin V, caspase-3/7 activity assays and cytochrome c release measurements are standard methods to quantify GO:0008630 activation after DNA damage. These assays define whether the pathway reaches the execution phase.
DNA damage and mitochondrial imaging
Immunofluorescence for gamma-H2AX marks DNA damage, while live-cell imaging of cytochrome c or mitochondrial membrane potential tracks mitochondrial outer membrane permeabilization. These methods localize the pathway in time and space.
Multi-omics profiling
Transcriptomics, proteomics and multi-omics approaches have been used to dissect cisplatin resistance mechanisms that converge on DNA-damage-induced apoptosis. Such datasets identify pathway genes whose expression predicts treatment response.
CRISPR functional genomics
CRISPR knockout and library screens test causal roles of candidate genes in the pathway, as shown by STAT5A knockout restoring TKI sensitivity. Combining screens with apoptosis readouts links genotype to cell death phenotype.
How CRISPR Can Be Used to Study GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
Knockout
CRISPR knockout is used to delete candidate genes such as STAT5A, TP53 or BAX and test whether DNA-damage-induced apoptosis is lost or restored. Knockout of STAT5A in resistant chronic myeloid leukemia cells restores TKI sensitivity, demonstrating causal involvement.
Point Mutation
Point-mutation knock-in models recreate disease-relevant variants in pathway genes, allowing researchers to test whether a specific amino acid change alters apoptotic commitment after DNA damage. This is especially valuable for TP53 and BCL2-family variants.
Knock-in
Tagged or reporter knock-in of genes such as CASP3 or APAF1 enables real-time monitoring of pathway activation in live cells. Knock-in of p53 target reporters can also quantify transcriptional activation after DNA damage.
Overexpression
Overexpression of anti-apoptotic genes such as BCL2 or MCL1 is used to test whether the pathway can be blocked and to model therapy resistance. Conversely, overexpression of pro-apoptotic effectors can sensitize cells to DNA-damaging agents.
How EDITGENE Supports intrinsic apoptotic signaling pathway in response to DNA damage Research
Researchers studying intrinsic apoptotic signaling pathway in response to DNA damage-related genes often need to determine whether a candidate gene is causally involved in DNA-damage-induced cell death or merely correlated with it. Rigorous causal testing requires isogenic models in which the gene is deleted, mutated, tagged or overexpressed, combined with quantitative apoptosis readouts.
Contact EDITGENE today to design your custom CRISPR model for intrinsic apoptotic signaling pathway in response to DNA damage research.
Frequently Asked Questions About intrinsic apoptotic signaling pathway in response to DNA damage
What is GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage?
It is the biological process in which an intracellular signal triggered by DNA damage activates intrinsic, mitochondrial apoptosis, ending when the execution phase of apoptosis begins.
What genes are involved in intrinsic apoptotic signaling pathway in response to DNA damage?
Key genes include TP53, BAX, BAK, BID, BBC3 (PUMA), PMAIP1 (NOXA), APAF1, CASP9, CASP3, CASP7, DFFB, BCL2, BCL2L1, MCL1 and STAT5A.
How is intrinsic apoptosis activated by DNA damage?
DNA damage activates p53 and BH3-only proteins, which trigger BAX/BAK pore formation, cytochrome c release, apoptosome assembly and caspase-9 activation.
Why is intrinsic apoptotic signaling important in cancer therapy?
Many anticancer therapies depend on this pathway to kill tumor cells, and its inactivation causes chemoresistance and relapse.
What is the role of TP53 in GO:0008630?
TP53 is stabilized after DNA damage and transcriptionally activates pro-apoptotic targets, including Caliban and BH3-only proteins.
How do BAX and BAK contribute to DNA-damage-induced apoptosis?
BAX and BAK form pores in the mitochondrial outer membrane, releasing cytochrome c and committing the cell to apoptosis.
What is the role of DFFB in apoptosis and persister cells?
DFFB participates in terminal DNA fragmentation and suppresses interferon signaling to enable cancer persister cell regrowth.
Can CRISPR knockout be used to study this pathway?
Yes, CRISPR knockout of genes such as STAT5A restores TKI sensitivity, demonstrating causal roles in the pathway.
What methods measure intrinsic apoptotic signaling after DNA damage?
Annexin V flow cytometry, caspase activity assays, cytochrome c release imaging, gamma-H2AX staining and multi-omics profiling are commonly used.
What diseases are linked to defects in DNA-damage-induced apoptosis?
Cancer chemoresistance, therapy relapse and stem cell survival abnormalities have been linked to altered pathway function.
Conclusion
GO:0008630, intrinsic apoptotic signaling pathway in response to DNA damage, is a central biological process that converts DNA damage into mitochondrial apoptosis through p53, BCL2-family effectors, the apoptosome and caspases. Its dysregulation underlies cancer chemoresistance, therapy relapse and altered stem cell survival, making it a high-value target for functional genomics. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with apoptosis and multi-omics readouts, provide the causal evidence needed to translate pathway knowledge into new therapeutic strategies.
References
- 1. Carneiro BA et al.. 2020. Targeting apoptosis in cancer therapy.. Nat Rev Clin Oncol 17(7):395-417 PMID: 32203277
- 2. Williams AF et al.. 2025. DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth.. Nat Cell Biol 27(12):2143-2151 PMID: 41249572
- 3. Shen Y et al.. 2025. Ints7 deficiency activates DNA damage response to elicit resurgence of endogenous retrovirus MERVL and anastasis of embryonic stem cells.. Nucleic Acids Res 53(15) PMID: 40842237
- 4. Çelik B et al.. 2026. Targeting STAT5A via CRISPR/Cas9 restores TKI sensitivity in resistant chronic myeloid leukemia cells.. Med Oncol 43(6) PMID: 42033509
- 5. Thangam R et al.. 2014. Activation of intrinsic apoptotic signaling pathway in cancer cells by Cymbopogon citratus polysaccharide fractions.. Carbohydr Polym 107:138-50 PMID: 24702929
- 6. Cui J et al.. 2025. Caliban is a transcriptional target of p53 in response to DNA damage.. PLoS One 20(8):e0331141 PMID: 40875638
- 7. Yue P et al.. 2023. Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches.. Mol Omics 19(4):297-307 PMID: 36723121
- 8. Kim R et al.. 2024. Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy.. Cancers (Basel) 16(5) PMID: 38473345
